Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Summary of Results: Adding Nonbiologic DMARDs to JIA Treatment
Adding methotrexate to anti-inflammatory treatments improves disease activity, as scored by physicians. The strength of evidence in support of this finding is moderate.
The results for other nonbiologic DMARDs are inconsistent and often statistically nonsignificant. For many outcomes, no observations are available. The evidence is insufficient to permit conclusions about benefits of nonbiologic DMARDs other than methotrexate.
Keywords: juvenile idiopathic arthritis | JIA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic DMARD | nonbiologic DMARD | non-biologic DMARD
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.